Diabetes, Obesity and Endocrine Research

A clinical research study including approximately 560 people with rare forms of obesity caused by genetic variants which looks at whether an investigational medication is safe and can improve the body’s ability to control weight and hunger in people with certain genetic variants.

The study focusses on five sub studies of Setmelanotide in obese patients with 6 specific gene defects in the Melanocortin-4 Receptor pathway. The trial provides evidence that feeling full after eating can be controlled by certain genes. You may be able to take part if you are 18-65 years of age and have been identified as having genetic variants that may lead to obesity.

This study will check if new insulin pump technology for type 1 diabetes affects eye health, as rapid blood sugar improvements might worsen diabetic eye disease.

This study tested a weekly injection of two weight-loss drugs (CagriSema) in people with obesity, showing up to 22.7% weight loss over 68 weeks.

This study tests a new treatment (CagriSema) for nerve pain in diabetes, with participants receiving weekly injections over 32 weeks.

This study tests a new treatment (setmelanotide) for rare genetic conditions that cause severe obesity by affecting the brain’s weight control system.

This study aims to screen people with type 2 diabetes or prediabetes in the community to find those at risk of liver disease, sleep apnoea and heart failure.